secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001723128-23-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance
--------------------------------------------------------------------------------

- Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.
- Net loss $7M ($0.05 loss per share) vs $2M loss last year; adjusted EPS $0.12 flat YoY.
- Adjusted EBITDA $116M, up 16% YoY; company reaffirms full-year 2023 guidance.
- Fourth and largest injectables facility successfully inspected; IPX203 PDUFA date June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/0001723128-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/amrx-20230505.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer